Registration number:
Medix-Care UK Ltd
for the Year Ended 31 January 2026
Medix-Care UK Ltd
Contents
|
Statement of Financial Position |
|
|
Notes to the Unaudited Financial Statements |
Medix-Care UK Ltd
(Registration number: 13168404)
Statement of Financial Position as at 31 January 2026
|
Note |
2026 |
2025 |
|
|
Fixed assets |
|||
|
Tangible assets |
- |
|
|
|
Investments |
|
- |
|
|
|
|
||
|
Current assets |
|||
|
Debtors |
|
|
|
|
Cash at bank and in hand |
|
|
|
|
|
|
||
|
Creditors: Amounts falling due within one year |
( |
( |
|
|
Net current assets/(liabilities) |
|
( |
|
|
Net assets |
|
|
|
|
Capital and reserves |
|||
|
Called up share capital |
200 |
200 |
|
|
Profit and loss account |
151,081 |
31,725 |
|
|
Shareholders' funds |
151,281 |
31,925 |
Medix-Care UK Ltd
(Registration number: 13168404)
Statement of Financial Position as at 31 January 2026 (continued)
For the financial year ending 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Directors' responsibilities:
|
• |
|
|
• |
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts. |
Approved and authorised by the
|
|
Medix-Care UK Ltd
Notes to the Unaudited Financial Statements for the Year Ended 31 January 2026
|
General information |
The company is a private company limited by share capital, incorporated in England and Wales.
The address of its registered office is:
United Kingdom
Principal activity
The principal activity of the company is that of information technology consultancy activities.
|
Accounting policies |
Summary of significant accounting policies and key accounting estimates
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.
Statement of compliance
These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).
Basis of preparation
These financial statements have been prepared using the historical cost convention.
The financial statements are prepared in sterling which is the functional currency of the entity.
Going concern
The financial statements have been prepared on a going concern basis.
Judgements and key sources of estimation uncertainty
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. |
Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. |
Medix-Care UK Ltd
Notes to the Unaudited Financial Statements for the Year Ended 31 January 2026 (continued)
|
2 |
Accounting policies (continued) |
Revenue recognition
Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of value added tax, returns, rebates and discounts.
The company recognises revenue when: the amount of revenue can be reliably measured; it is probable that future economic benefits will flow to the entity; and specific criteria have been met for each of the company's activities.
Tax
The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.
The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.
Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.
Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used.
Tangible assets
Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.
Depreciation
Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:
Medix-Care UK Ltd
Notes to the Unaudited Financial Statements for the Year Ended 31 January 2026 (continued)
|
2 |
Accounting policies (continued) |
Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.
Investment property
Business combinations
Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.
Investments
Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.
Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value. In the statement of financial position, bank overdrafts are shown within borrowing or current liabilities
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Costs include all costs of purchase, costs of conversion and other costs incurred in bringing the stocks to their present location and condition.
Medix-Care UK Ltd
Notes to the Unaudited Financial Statements for the Year Ended 31 January 2026 (continued)
|
2 |
Accounting policies (continued) |
Financial instruments
Recognition and measurement
Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.
|
Staff numbers |
The average number of persons employed by the company (including directors) during the year, was
|
Tangible assets |
|
Land and buildings |
Total |
|
|
Cost or valuation |
||
|
At 1 February 2025 |
|
|
|
Revaluations |
|
|
|
Disposals |
( |
( |
|
At 31 January 2026 |
- |
- |
|
Depreciation |
||
|
At 1 February 2025 |
|
|
|
Eliminated on disposal |
( |
( |
|
At 31 January 2026 |
- |
- |
|
Carrying amount |
||
|
At 31 January 2026 |
- |
- |
|
At 31 January 2025 |
|
|
Included within the net book value of land and buildings above is £nil (2025 - £234,111) in respect of freehold land and buildings.
The property has been transferred to Medix Investments Limited, a subsidiary company during the financial year.
Medix-Care UK Ltd
Notes to the Unaudited Financial Statements for the Year Ended 31 January 2026 (continued)
|
Investments |
|
2026 |
2025 |
|
|
Investments in subsidiaries |
|
- |
|
Subsidiaries |
£ |
|
Cost or valuation |
|
|
Additions |
|
|
Provision |
|
|
Carrying amount |
|
|
At 31 January 2026 |
|
|
Debtors |
|
2026 |
2025 |
|
|
Amounts owed by related parties |
|
- |
|
Other debtors |
|
|
|
Prepayments |
- |
|
|
Deferred tax assets |
- |
|
|
|
|
|
Creditors |
Creditors: amounts falling due within one year
|
Note |
2026 |
2025 |
|
|
Amounts owed to group undertakings and undertakings in which the company has a participating interest |
- |
|
|
|
Accruals and deferred income |
|
|
|
|
Other creditors |
|
|
|
|
|
|
Medix-Care UK Ltd
Notes to the Unaudited Financial Statements for the Year Ended 31 January 2026 (continued)
|
Reserves |
The changes to each component of equity resulting from items of other comprehensive income for the current year were as follows:
|
|
Profit and loss account:
This reserve records retained earnings and accumulated losses.
|
Related party transactions |
Summary of transactions with subsidiaries
The investment property was transferred to the subsidiary company during the year at market value. A loan equal to the market value has been provided to the subsidiary company. No repayment terms or interest will be charged on the liability.
Loans to / (from) related parties
|
2026 |
Entities with joint control or significant influence |
Total |
|
At start of period |
( |
( |
|
Advanced |
|
|
|
Repaid |
( |
( |
|
At end of period |
|
|
|
|
||
|
2025 |
Entities with joint control or significant influence |
Total |
|
At start of period |
|
|
|
Repaid |
( |
( |
|
At end of period |
( |
( |
|
|
||